# AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

> **NCT00976911** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 361 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** liposomal doxorubicin
- **DRUG:** paclitaxel
- **DRUG:** topotecan

## Key facts

- **NCT ID:** NCT00976911
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10-29
- **Primary completion:** 2014-07-09
- **Final completion:** 2014-07-09
- **Target enrollment:** 361 (ACTUAL)
- **Last updated:** 2022-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00976911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00976911, "AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00976911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*